Discovery and application of fructus cannabis oil in relieving ulcerative colitis
Hemp seed oil solves the problem of limited efficacy of the existing technology by inhibiting the HMGB1/RAGE inflammation pathway, reducing NF-κB expression, and alleviating the inflammatory response of ulcerative colitis. It provides a new method for treating UC, with a broad clinical practice. Application prospects.
Patent Information
- Application Number
- CN202410954818.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-09
- Publication Date
- 2024-11-22
AI Technical Summary
The prior art has limited efficacy in the treatment of ulcerative colitis (UC), and its inhibitory mechanism on the HMGB1/RAGE inflammation pathway is unclear, making it difficult to effectively alleviate the inflammatory response.
Hemp seed oil is pressed by room temperature pressing method. After net selection, it is used to reduce the colonic inflammatory response in the UC rat model, inhibit the expression of HMGB1/RAGE inflammatory pathway, reduce the expression of NF-κB mRNA and protein, and thus reduce the proinflammatory factors. The expression of TNF-α increases the expression of the antiinflammatory factor IL-10.
Hemp seed oil effectively reduces the colonic inflammatory response in UC rat model, reduces the disease activity index, inhibits the HMGB1/RAGE inflammation pathway, and improves the expression of IL-10, providing a new way of treating UC and has clinical application prospects.
Smart Images

Figure CN118987079A_ABST
Abstract
Description
Technical Field
[0001] The invention discloses the discovery and use of hemp seed oil in alleviating ulcerative colitis (UC) inflammatory response and inhibiting HMGB1 / RAGE inflammatory pathway, and belongs to the field of medical technology. Background Art
[0002] Ulcerative colitis (UC) is a chronic inflammatory bowel disease. UC is a major type of IBD, characterized by high morbidity and complex course, and is one of the intractable diseases worldwide. UC can cause intestinal barrier dysfunction, increased intestinal permeability, microbial invasion of the mucosal immune system, leading to uncontrolled inflammatory response and promoting the secretion of cytokines and chemokines (tumor necrosis factor [TNF]-α, interleukin [IL]-1β, IL-8 and CC motif chemokine ligand [CCL]-20). These cytokines interact with the intestinal microbiome and mucosal immune system mediated by the mucosal immune system, causing the body's inflammation to gradually worsen. Modern medicine believes that the onset of UC is related to family inheritance, lifestyle, inflammatory immune factors, intestinal microbial environment and intestinal mucosal barrier. The main treatment measures currently include drug control of inflammation, immunomodulation, mucosal healing and repair, and surgery. Traditional Chinese medicine believes that its pathogenesis is based on spleen and stomach weakness, and adopts a variety of treatment methods such as oral administration of Chinese medicine, acupuncture, and enema. Although these treatment methods can improve the symptoms of UC, the clinical efficacy needs to be improved. Therefore, it is very necessary to find more effective treatment methods.
[0003] High mobility group protein B1 (HMGB1) is a damage-associated molecular pattern. It can be released into the extracellular space under external signal stimulation to participate in various immune responses, thereby promoting inflammatory responses, and is therefore called an "alarmin". Studies have shown that HMGB1 plays an important role in a variety of inflammatory diseases, such as inflammatory bowel disease and Helicobacter pylori infection-related gastric mucosal inflammation. Functional polymorphisms in the regulatory elements and ligand binding regions of the advanced glycation end product (RAGE) gene affect the expression and function of RAGE, thereby increasing susceptibility to UC. In some inflammatory responses of the body, when HMGB1 binds to RAGE, it activates nuclear transcription factor-κB (NF-κB). The NF-κB-related inflammatory pathway plays a major role in the formation and development of UC. Currently, many studies target NF-κB, which is widely used in the treatment and prevention of inflammatory diseases. Studies have shown that Chinese medicine monomers and single drugs can inhibit the development of UC by reducing mucosal inflammatory response, inhibiting intestinal epithelial cell apoptosis, enhancing intestinal mucosal barrier, and regulating the abundance of intestinal flora through the NF-κB signaling pathway. Its mechanism of action may be related to regulating the TLR4 / NF-κB signaling pathway, NF-κB / NLRP3 signaling pathway, JAK2 / STAT3 / NF-κB signaling pathway, PI3K / AKT / NF-κB signaling pathway, etc.
[0004] Under the guidance of theories such as syndrome differentiation and treatment, traditional Chinese medicine uses symptomatic medication for the causes of UC. For example, for constipation caused by physical weakness, hemp seed oil and other "intestinal laxative" drugs or compound prescriptions are often used, and the effect is often satisfactory. Hemp seed oil and water extract can relieve constipation, promote the restoration of balance of disordered intestinal flora, reduce colonic inflammatory damage in model animals, and regulate the expression of TLRs signaling pathways. Previous studies have shown that hemp seed oil can relieve constipation, improve blood circulation, regulate immunity, and reduce free radical damage in constipated or aging model animals; it has a regulatory effect on the in vitro growth or in vivo colonization of a variety of intestinal bacteria; studies have shown that hemp seed oil can improve the symptoms of UC model rats by regulating the diversity of intestinal flora, increasing beneficial bacteria and reducing harmful bacteria. However, the exact mechanism by which hemp seed oil alleviates UC needs to be further clarified. Summary of the invention
[0005] The invention provides a discovery and use of hemp seed oil in alleviating ulcerative colitis (UC) inflammatory response and inhibiting the expression of HMGB1 / RAGE inflammatory pathway, characterized in that hemp seed oil can alleviate colonic inflammatory response in UC rat models, inhibit the expression of HMGB1 / RAGE inflammatory pathway in UC rat models, and reduce the expression of HMGB1, RAGE, NF-κB mRNA and protein in colon tissue of UC rats, thereby reducing the expression of TNF-α, a pro-inflammatory factor downstream of the pathway, and increasing the expression of IL-10, an anti-inflammatory factor;
[0006] The hemp seed oil used in the present invention comes from hemp seeds, which are cleaned and peeled and then squeezed by a normal temperature pressing method, with an oil yield of 18.0%, a specific gravity of 0.920 g / ml, and stored at 4°C;
[0007] Through experiments, it was found that in animal experiments, hemp seed oil can effectively reduce the colonic inflammation response of UC rat models, and the three indicators of rat weight, stool viscosity, and fecal occult blood were evaluated, and the disease activity index DAI score was reduced;
[0008] Through experiments, it was found that in animal experiments, hemp seed oil can inhibit the expression of HMGB1 / RAGE inflammatory pathway in the colon tissue of UC rats, thereby reducing colon inflammatory response;
[0009] Through experiments, it was found that in animal experiments, hemp seed oil can reduce the expression of HMGB1, RAGE, NF-κB mRNA and protein in the colon tissue of UC rats;
[0010] Through experiments, it was found that in animal experiments, hemp seed oil can reduce the expression of pro-inflammatory factor TNF-α in colon tissue and serum of UC rats;
[0011] Through experiments, it was found that in animal experiments, hemp seed oil can increase the expression of anti-inflammatory factor IL-10 in colon tissue and serum of UC rats;
[0012] The inventors of the present invention discovered for the first time that hemp seed oil can reduce the colonic inflammatory response of UC rat models, inhibit the HMGB1 / RAGE inflammatory pathway, and effectively reduce the expression of HMGB1, RAGE, NF-κB mRNA and protein, thereby reducing the expression of the pro-inflammatory factor TNF-α downstream of the pathway and increasing the expression of the anti-inflammatory factor IL-10; they were the first to confirm that hemp seed oil may reduce the colonic inflammatory response of UC rats by inhibiting the HMGB1 / RAGE inflammatory pathway, which provides a new idea for the clinical use of hemp seed oil to supplement and relieve UC, and has broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Figure 1 This is a comparison of the disease activity index (DAI) scores of rats in the blank group, UC model group, hemp seed oil group and positive control group;
[0014] Figure 2 The results of Real-time PCR detection of HMGB1 and RAGE mRNA expression in colon tissue of rats in the blank group, UC model group, hemp seed oil group and positive control group;
[0015] Figure 3The results of Western blot detection of HMGB1, RAGE, and NF-κB protein expression in colon tissue of rats in the blank group, UC model group, hemp seed oil group, and positive control group;
[0016] Figure 4 The results of ELISA detection of pro-inflammatory factor TNF-α in colon tissue and serum of rats in blank group, UC model group, hemp seed oil group and positive control group [level changes;
[0017] Figure 5 This is the result of ELISA detection of the changes in the levels of anti-inflammatory factor IL-10 in the colon tissue and serum of rats in the blank group, UC model group, hemp seed oil group and positive control group. DETAILED DESCRIPTION
[0018] 1. Experimental animals and groups:
[0019] Forty SPF SD rats (male rats, mass 200-250 g, purchased from Wu's Experimental Animal Research Center, Fuzhou, Fujian Province, with the experimental animal use license number SCXK (Min) 2016-0002) were used in this study. After one week of adaptive feeding, the 40 SD rats were randomly divided into the following 4 groups: blank group, UC model group, hemp oil group, and positive control group, with 10 rats in each group;
[0020] 2. Establishment of UC rat model:
[0021] Dextran sulfate sodium salt (DSS) was used to establish an ulcerative colitis (UC) rat model. 40 SD rats were randomly divided into a blank group, a UC model group, a hemp seed oil group (hemp seeds were identified, cleaned and peeled, and the oil was extracted by normal temperature pressing, with an oil yield of 18.0%, a specific gravity of 0.920 g / ml, and a dosage of hemp seed oil 1 g / kg) and a positive control group (sulfasalazine, 300 mg / kg), with 10 rats in each group; the rats in the blank group and the UC model group were gavaged with 0.5% polysorbate 80, and the rats in the hemp seed oil group and the positive control group were gavaged with the corresponding drug solution once a day for 10 consecutive days; starting from the 4th day, the rats in the UC model group, the hemp seed oil group and the positive control group drank 4% DSS solution for 7 consecutive days to establish the UC model. The body weight and disease activity index (DAI) score of the rats were recorded;
[0022] 3. Disease Activity Index (DAI) score of rats:
[0023] The assessment and scoring are based on three aspects, namely weight, stool viscosity, and fecal occult blood. The DAI score is the sum of the three indicators.
[0024]
[0025]
[0026] 4. Real-time PCR detection of HMGB1 / RAGE inflammatory pathway key factors HMGB1, RAGE mRNA expression:
[0027] The rat colon tissue was added with Lysis Buffer reagent and fully ground in a homogenizer. The total RNA of the colon tissue was extracted according to the instructions of the kit. The OD260 / 280 was measured with a microspectrophotometer to obtain the RNA concentration and purity. The total RNA was synthesized into cDNA by reverse transcription, and then the cDNA was used as a template to detect the mRNA expression level of the target gene by Real-time PCR. β-actin was used as the internal reference gene. The amplification system: cDNA 1uL, upstream / downstream primers 0.5uL each, SYBR qPCRMaster Mix II 10uL, and enzyme-free water was added to make up to 20uL; the amplification conditions were as follows: the first stage: 95℃ 30s 1 cycle; the second stage: 95℃ 5s 40 cycles; the third stage: 60℃ 30s 1 cycle. The specific sequences of primers are as follows: HMGB1 upstream primer: 5'-GGAGATCCTAAGAAGCCGAGA-3'; downstream primer 5'-CATGGTCTTCCACCTCTCTGA-3'; RAGE upstream primer: upstream: 5'-CGGCTGGTGTTCCCAATAA-3', downstream: 5'-TGTTCCTTCACAGATACTCCCT-3'; β-actin upstream primer: 5'-TGACGTGGACATCCGCAAAG-3'; downstream primer 5'-CTGGAAGGTGGACAGCGAGG-3'. Real-time PCR (2 -ΔΔCT Method) to detect the relative expression of key factors HMGB1 and RAGE mRNA in rat colon tissue;
[0028] 5. Western blot detection of HMGB1 / RAGE inflammatory pathway HMGB1, RAGE, NF-κB protein expression:
[0029] The colon tissue was taken out from the -80°C refrigerator, weighed quickly, cut into pieces and put into a pre-cooled homogenization tube containing protein lysis solution (containing PSFM and phosphorylase inhibitor), and allowed to stand for 30 minutes after sufficient homogenization, and centrifuged at 12000r / m and 4°C for 20 minutes. The obtained supernatant was the total protein of the colon tissue, which was divided into sterilized Eppendorf centrifuge tubes and frozen in a -80°C refrigerator to avoid repeated freezing and thawing (all the above operations were performed on ice to reduce protein degradation); protein quantification was performed using the BCA method; 10% SDS-PAGE gel was prepared, and an equal amount of protein was added to the protein lane, with a constant voltage of 80V for 30 minutes. After the sample was compressed into a straight line, it was adjusted to a constant voltage of 100V for 1 hour. 30min, observe the electrophoresis bands, and stop electrophoresis when bromophenol blue runs to the bottom; transfer the protein to the PVDF membrane at a constant current of 200mA for 2h; block with 5% skim milk powder at room temperature for 1h; incubate with primary antibody at 4℃ overnight; the next day, discard the stock solution, wash the membrane, add the corresponding diluted secondary antibody, incubate at 37℃ for 1h, wash the membrane again, develop with ECL luminescent solution, take pictures with gel imaging system, analyze the gray value of protein bands with Image J software, take β-actin as internal reference protein, and take the ratio of target protein gray value / reference protein gray value as the relative expression level of target protein;
[0030] 6.ELISA detection of serum cytokines:
[0031] Blood was collected from the orbits of rats in each group. After the whole blood samples were kept at 4°C overnight, they were centrifuged at 1000×g for 20 min, and the supernatant was collected. Specific ELISA kits were used to detect the levels of cytokines TNF-α and IL-10 in the colon tissue and serum of rats in each group. The experimental steps were carried out strictly according to the instructions of the kit;
[0032] 7. Statistical methods:
[0033] GraphPad Prism 9.4.1 statistical software was used for analysis, and Image J software was used for Western blot band grayscale analysis. The experimental data were expressed as (x±s, and one-way analysis of variance was used to compare the means among multiple samples, with P<0.05 as statistically significant).
[0034] Embodiment 1:
[0035] Experimental purpose: To explore the effect of hemp seed oil on UC rats by recording the weekly weight change and disease activity index (DAI) score of each group of rats;
[0036] Experimental design: Rats were weighed and recorded weekly, the percentage of weight loss was calculated, the fecal viscosity and fecal occult blood of rats were observed, DAI scores were performed, and GraphPad Prism 9.4.1 statistical software was used for analysis and drawing; the results are shown in Figure 1 As shown;
[0037] Result analysis: The DAI level of rats in the hemp seed oil group was lower than that in the UC model group;
[0038] Results show that hemp seed oil can reduce the increase in the disease activity index of rats caused by ulcerative colitis;
[0039] Embodiment 2:
[0040] Experimental purpose: To detect the expression of HMGB1 and RAGE mRNA in rat colon tissue by Real-time PCR technology, and to examine the effect of hemp seed oil on the expression of HMGB1 / RAGE inflammatory pathway in colon tissue of UC rats;
[0041] Experimental design: RNA was extracted from the colon tissue of each group of rats and reverse transcribed into cDNA. Real-time PCR was used to detect the expression of HMGB1 and RAGE mRNA in colon tissue. Primer sequences were designed and primer specificity was verified. According to the CT value of the amplification curve, 2 -ΔΔct GraphPad Prism 9.4.1 statistical software was used for analysis and drawing. Figure 2 As shown;
[0042] Result analysis: The expression of HMGB1 and RAGE mRNA in colon tissue of rats in hemp seed oil group was lower than that in UC model group;
[0043] The results showed that hemp seed oil alleviated the colonic inflammatory response in UC rats, which may be related to the inhibition of the expression of HMGB1 / RAGE inflammatory pathway;
[0044] Embodiment three:
[0045] Experimental purpose: To detect the expression of HMGB1, RAGE, and NF-kB proteins in rat colon tissue by Western blot technology. To detect the effect of hemp seed oil on the expression of HMGB1 / RAGE inflammatory pathway in colon tissue of UC rats;
[0046] Experimental design: The colon tissue proteins of rats in each group were extracted, and the expression of HMGB1, RAGE, and NF-kB proteins in colon tissue was detected by Western blot technology. The gray value of the bands was analyzed by Image J according to the blot band diagram, and the GraphPad Prism 9.4.1 statistical software was used for analysis and drawing. Figure 3 As shown;
[0047] Result analysis: The expression of HMGB1, RAGE and NF-kB proteins in colon tissue of rats in hemp seed oil group was lower than that in UC model group;
[0048] The results showed that hemp seed oil alleviated the colonic inflammatory response and reduced the disease activity index in UC rats, which may be related to the inhibition of the expression of the HMGB1 / RAGE / NF-kB inflammatory pathway;
[0049] Embodiment 4:
[0050] Experimental purpose: To detect the content of pro-inflammatory factor TNF-α in rat colon tissue and serum by ELISA technique;
[0051] Experimental design: After serum treatment, the content of pro-inflammatory factor TNF-α in rat colon tissue and serum was detected by ELISA technology. Figure 4 As shown;
[0052] Result analysis: The expression of pro-inflammatory factor TNF-α in colon tissue and serum of rats in hemp seed oil group was lower than that in UC model group;
[0053] The results showed that hemp seed oil could inhibit the HMGB1 / RAGE inflammatory signaling pathway, thereby effectively alleviating colon inflammation in UC rats;
[0054] Embodiment five:
[0055] Experimental purpose: To detect the content of anti-inflammatory factor IL-10 in rat colon tissue and serum by ELISA technique;
[0056] Experimental design: After serum treatment, the content of anti-inflammatory factor IL-10 in rat colon tissue and serum was detected by ELISA technology. Figure 5 As shown;
[0057] Result analysis: The expression of anti-inflammatory factor IL-10 in serum of rats in hemp seed oil group was higher than that in UC model group;
[0058] The results showed that hemp seed oil could inhibit the HMGB1 / RAGE inflammatory signaling pathway, thereby effectively alleviating colon inflammation in UC rats;
[0059] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the technical principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. The discovery and use of hemp seed oil to alleviate ulcerative colitis, characterized in that: Hemp seed oil can alleviate the colonic inflammatory response in the UC rat model, inhibit the expression of the HMGB1 / RAGE inflammatory pathway in the UC rat model, and reduce the expression of HMGB1, RAGE, NF-κB mRNA and protein in the colon tissue of UC rats, thereby reducing the expression of the downstream pro-inflammatory factor TNF-α in the pathway and increasing the expression of the anti-inflammatory factor IL-10.
2. The discovery and use of hemp seed oil for alleviating ulcerative colitis as claimed in claim 1, wherein the hemp seed oil is from hemp seed, which is cleaned and peeled and then pressed at room temperature to produce oil with an oil yield of 18.0%, a specific gravity of 0.920 g / ml, and is stored at 4°C.
Citation Information
Patent Citations
Application of sophora japonica and elm composition in preparation of medicine for preventing or treating inflammatory bowel disease
CN115969914A
Application of trans-astaxanthin in relieving stomach inflammation caused by H.pylori infection
CN116196302A
Cited By
Application of cannabis sativa in preparation of medicine for preventing and / or treating chicken necrotic enteritis disease
CN121287767A
